Compare · ARGX vs IVVD
ARGX vs IVVD
Side-by-side comparison of argenx SE (ARGX) and Invivyd Inc. (IVVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IVVD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.52B, about 207.5x IVVD ($262.7M).
- Over the past year, ARGX is up 62.3% and IVVD is up 22.7% - ARGX leads by 39.6 points.
- IVVD has been more active in the news (5 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- argenx SE
- Invivyd Inc.
- Price
- $878.05-0.58%
- $0.89+2.84%
- Market cap
- $54.52B
- $262.7M
- 1M return
- +9.78%
- -25.96%
- 1Y return
- +62.32%
- +22.74%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest IVVD
- Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
- Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
- Invivyd to Participate in Upcoming Investor Events
- SEC Form 4 filed by Director Royan Ajay
- SEC Form 4 filed by Director Mcguire Terrance
- SEC Form 4 filed by Director Mclaughlin Kevin F
- SEC Form 4 filed by Director Elia Marc
- SEC Form 4 filed by Director Bolno Paul